Valuation : Rani Therapeutics Holdings, Inc.

Market Cap 98.6M 84.61M 79.27M 72.52M 137M 9.42B 137M 937M 366M 4.75B 370M 362M 15.71B P/E 2026 *
-4.93x
P/E 2027 * -4.5x
Enterprise Value 98.6M 84.61M 79.27M 72.52M 137M 9.42B 137M 937M 366M 4.75B 370M 362M 15.71B EV / Sales 2026 *
15.8x
EV / Sales 2027 * 14.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+1.52%
1 week-6.81%
Current month+10.35%
1 month+0.39%
3 months-9.18%
6 months-38.10%
Current year-36.73%
1 week 0.84
Extreme 0.84
0.9
1 month 0.75
Extreme 0.752
0.93
Current year 0.61
Extreme 0.6126
1.54
1 year 0.44
Extreme 0.4404
3.87
3 years 0.39
Extreme 0.387
8.75
5 years 0.39
Extreme 0.387
36.27
10 years 0.39
Extreme 0.387
36.27
Manager TitleAgeSince
Chief Executive Officer 45 01/06/2021
Director of Finance/CFO 46 29/06/2026
Chief Tech/Sci/R&D Officer 42 01/01/2022
Director TitleAgeSince
Chairman 69 01/06/2021
Director/Board Member 80 01/09/2018
Director/Board Member 69 06/04/2021
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Free

Director

247,200 0.2479%
01/08/26 Other

Director

12,500 0.0125%
21/07/26 Buy

Founder

36,000 0.0361%
Change 5-day change 1-year change 3-year change Capi.($)
+1.52%-6.81%+44.05%-77.58% 97.12M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+3.40%+51.59%+93.39% 65.4B
-1.03%-1.52%+6.31%-5.28% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-2.41%-7.09%-8.16%+455.82% 27.16B
+0.37%+0.70%+37.37%-15.78% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.50%+1.60%+44.13%+151.30% 13.9B
Average +0.63%+0.22%+56.86%+166.01% 28.84B
Weighted average by Cap. +1.11%+0.72%+55.94%+155.02%

Financials

2026 *2027 *
Net sales 6.26M 5.37M 5.03M 4.6M 8.67M 598M 8.7M 59.47M 23.25M 301M 23.49M 22.98M 997M 6.63M 5.69M 5.33M 4.88M 9.19M 634M 9.22M 63.04M 24.64M 319M 24.9M 24.36M 1.06B
Net income -31.46M -27M -25.29M -23.14M -43.58M -3.01B -43.73M -299M -117M -1.51B -118M -116M -5.01B -36.73M -31.52M -29.53M -27.02M -50.87M -3.51B -51.05M -349M -136M -1.77B -138M -135M -5.85B
Net Debt - -
Logo Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Employees
70
Date Price Change Volume
27/08/26 $0.8542 +1.52% 310,577
26/08/26 $0.8414 -5.57% 539,894
25/08/26 $0.8910 +1.37% 782,316
24/08/26 $0.8790 -0.11% 471,822
21/08/26 $0.8800 +3.41% 708,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8542USD
Average target price
7.200USD
Spread / Average Target
+742.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RANI Stock